INT116709

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.10
First Reported 2004
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 5
Total Number 5
Disease Relevance 4.48
Pain Relevance 3.97

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Mapk4) cell cycle (Mapk4) cytoplasm (Mapk4)
Mapk4 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Brush evoked pain 10 99.96 Very High Very High Very High
cINOD 11 99.62 Very High Very High Very High
Spontaneous pain 2 99.08 Very High Very High Very High
allodynia 6 98.92 Very High Very High Very High
Cancer pain 5 97.92 Very High Very High Very High
Dopamine 54 96.00 Very High Very High Very High
Inflammation 19 94.04 High High
Dorsal horn 2 93.56 High High
Spinal cord 8 90.88 High High
cytokine 9 84.52 Quite High
Disease Link Frequency Relevance Heat
Neuropathic Pain 18 99.96 Very High Very High Very High
Pain 11 98.60 Very High Very High Very High
Cancer Pain 5 97.92 Very High Very High Very High
Stress 68 95.04 Very High Very High Very High
INFLAMMATION 26 94.04 High High
Cancer 4 91.20 High High
Nervous System Injury 7 88.64 High High
Injury 7 87.64 High High
Hypersensitivity 1 73.68 Quite High
Death 9 73.12 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Moreover, intraspinal administration of a p38MAPK inhibitor, SB203580, suppressed the allodynia.
Negative_regulation (inhibitor) of p38MAPK associated with allodynia
1) Confidence 0.10 Published 2004 Journal J. Pharmacol. Sci. Section Abstract Doc Link 14978347 Disease Relevance 0.91 Pain Relevance 1.05
On the other hand, a 3-day administration [4 microg/rat/day, intrathecally (i.t.)] of 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole (SB203580), an inhibitor of p38MAPK, could suppress tactile allodynia and spontaneous pain of the bone cancer pain rats and decrease the phosphorylation of p38 as well as the expression of IL-1beta and TNF-alpha.
Negative_regulation (suppress) of p38MAPK associated with pain, brush evoked pain, cancer pain and spontaneous pain
2) Confidence 0.05 Published 2010 Journal Brain Res. Section Abstract Doc Link 20478276 Disease Relevance 1.29 Pain Relevance 1.06
Moreover, intraspinal administration of p38MAPK inhibitor, SB203580, suppressed the allodynia.
Negative_regulation (inhibitor) of p38MAPK associated with allodynia
3) Confidence 0.04 Published 2004 Journal Novartis Found. Symp. Section Abstract Doc Link 15469044 Disease Relevance 1.16 Pain Relevance 1.06
In addition, both studies agree that P-p38MAPK levels are unaffected.
Neg (unaffected) Negative_regulation (unaffected) of p38MAPK
4) Confidence 0.01 Published 2004 Journal BMC Neurosci Section Body Doc Link PMC526203 Disease Relevance 0.30 Pain Relevance 0.11
Celecoxib (at low dose) [57,58] and other NSAIDs (and minocycline) inhibit p38MAPK leading to a decrease in COX-2 production, decreased mRNA stability and decreased PGE2 release.
Negative_regulation (inhibit) of p38MAPK associated with cinod
5) Confidence 0.01 Published 2004 Journal J Neuroinflammation Section Body Doc Link PMC483059 Disease Relevance 0.82 Pain Relevance 0.69

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox